Morgan Stanley’s Applied Molecular Transport Inc. Common Stock AMTI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q4
Sell
-5,825
Closed -$914 7939
2023
Q3
$914 Sell
5,825
-7,184
-55% -$1.91K ﹤0.01% 7245
2023
Q2
$3.36K Sell
13,009
-425,850
-97% -$121K ﹤0.01% 7075
2023
Q1
$140K Buy
438,859
+427,395
+3,728% +$223K ﹤0.01% 5869
2022
Q4
$4.82K Sell
11,464
-397,311
-97% -$400K ﹤0.01% 7159
2022
Q3
$398K Sell
408,775
-643,548
-61% -$1.14M ﹤0.01% 5381
2022
Q2
$3.06M Buy
1,052,323
+40,164
+4% +$169K ﹤0.01% 4189
2022
Q1
$7.61M Buy
1,012,159
+467,263
+86% +$3.87M ﹤0.01% 3225
2021
Q4
$7.62M Buy
544,896
+332,412
+156% +$6.55M ﹤0.01% 3254
2021
Q3
$5.5M Buy
212,484
+194,936
+1,111% +$6.18M ﹤0.01% 3584
2021
Q2
$802K Buy
17,548
+10,842
+162% +$513K ﹤0.01% 5213
2021
Q1
$295K Sell
6,706
-102,130
-94% -$4.97M ﹤0.01% 5432
2020
Q4
$3.35M Buy
108,836
+103,995
+2,148% +$3.3M ﹤0.01% 3697
2020
Q3
$154K Buy
+4,841
New +$119K ﹤0.01% 5234

Other funds holding AMTI

Morgan Stanley's AMTI Position: Q4 2023 in Review

Morgan Stanley sold out of Applied Molecular Transport Inc. Common Stock (AMTI) in Q4 2023, closing a stake of 5,825 shares — an estimated $914 sold.

Morgan Stanley first reported a position in AMTI in Q3 2020 and held it in 13 quarters. The position peaked at $7.62M in Q4 2021. 2 funds tracked by Wall St. Rank hold AMTI as of Q4 2023.

  • Morgan Stanley reported no remaining Applied Molecular Transport Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
  • Morgan Stanley sold 5,825 Applied Molecular Transport Inc. Common Stock shares in Q4 2023, an estimated $914.
  • Morgan Stanley first reported a position in Applied Molecular Transport Inc. Common Stock in Q3 2020 and held it in 13 quarters.
  • Morgan Stanley's Applied Molecular Transport Inc. Common Stock position peaked at $7.62M in Q4 2021.
  • 2 funds tracked by Wall St. Rank held Applied Molecular Transport Inc. Common Stock as of Q4 2023.

Based on Morgan Stanley's 13F filing for Q4 2023, filed 13 Feb 2024.